Axsome Therapeutics Has Dosed The First Patient In The FOCUS Phase 3 Trial Of Solriamfetol, An Investigational Treatment For Attention Deficit Hyperactivity Disorder In Adults
Portfolio Pulse from Benzinga Newsdesk
Axsome Therapeutics has dosed the first patient in the FOCUS Phase 3 trial of Solriamfetol, an investigational treatment for Attention Deficit Hyperactivity Disorder in adults.
July 07, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics has initiated the FOCUS Phase 3 trial of Solriamfetol, a potential treatment for adult ADHD.
The initiation of a Phase 3 trial is a significant milestone in drug development. This news could positively impact Axsome Therapeutics' stock as it indicates progress in the development of Solriamfetol, a potential new treatment for adult ADHD.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100